The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
Open accessAbstract
Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse-free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56 bright NK cells had decreased relapse-free survival. In addition, the TNF-α/IFN-γ cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Cited by
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
Self-citationChronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0071 · Cited by 277
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30094-8 · Cited by 195
Metadata
- Authors
- Ilander, M., Olsson-Strömberg, U., Schlums, H., Guilhot, J., Brück, O., Lähteenmäki, H., Kasanen, T., Koskenvesa, P., Söderlund, S., Höglund, M., Markevärn, B., Själander, A., Lotfi, K., Dreimane, A., Lübking, A., Holm, E., Björeman, M., Lehmann, S., Stenke, L., Ohm, L., Gedde-Dahl, T., Majeed, W., Ehrencrona, H., Koskela, S., Saussele, S., Mahon, F.-X., Porkka, K., Hjorth-Hansen, H., Bryceson, Y. T., Richter, J., & Mustjoki, S.
- Venue
- Leukemia
- Published
- 2016-11-28
- Volume
- 31
- Issue
- 5
- Pages
- 1108-1116
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2557854027
- Cited by
- 250
- References
- 3
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. https://app.cochat.ai/papers/10.1038/leu.2016.360
- The paper
- Ilander, M., Olsson-Strömberg, U., Schlums, H., Guilhot, J., Brück, O., Lähteenmäki, H., Kasanen, T., Koskenvesa, P., Söderlund, S., Höglund, M., Markevärn, B., Själander, A., Lotfi, K., Dreimane, A., Lübking, A., Holm, E., Björeman, M., Lehmann, S., Stenke, L., . . . Mustjoki, S. (2017). Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. https://doi.org/10.1038/leu.2016.360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.